Trusted Press Release Distribution   Plans | Login    

Briefing Search


Author Details
Phillip Fleck

Bookmark and Share
CURE Pharmaceutical Issues Letter to Shareholders
This certification positions CURE’s manufacturing capabilities at the forefront of quality standards set by the various regulatory agencies., 11/21/2020 - CURE Pharmaceutical Holdings Stock Symbol: (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.

Highlights of the letter include:

Formulations include a sleep aid called Sleep A.S.A.P.™, EnergY™ designed to enhance performance and mental focus, an electrolyte and muscle recovery product called RecoverB™, and immunD™ for immune support.

CURR earning NSF International, cGMP certification for its 25,000 square foot manufacturing facility

This certification enables manufacturers to become independently certified by NSF as complying with cGMP requirements as listed in Section 8 of NSF/ANSI Standard 173. This certification positions CURE’s manufacturing capabilities at the forefront of quality standards set by the various regulatory agencies.

The Company’s recent pharmacokinetic (PK) study on its 25mg cannabidiol (CBD) oral thin film (OTF) showing improved bioavailability of cannabidiol in healthy subjects

About SeraLabs

SeraLabs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD. SeraLabs® creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names SeraRelief™, SeraTopical™, SeraLabs™, Gordon’s Herbals™ and SeraPets™. SeraLabs® sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, SeraLabs® products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: and follow @theseralabs

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

For more info on Stock Symbol: CURR visit:


FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2021 Proserve Technology, Inc.